Product
Carisbamate
Aliases
YKP509
3 clinical trials
2 indications
Indication
Lennox-Gastaut syndromeIndication
SeizureClinical trial
Phase 1, Open-Label Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut SyndromeStatus: Completed, Estimated PCD: 2022-12-14
Clinical trial
Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut SyndromeStatus: Completed, Estimated PCD: 2022-05-23
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label ExtensionStatus: Recruiting, Estimated PCD: 2025-06-01